{"id":"everolimus-tacrolimus-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Everolimus is an mTOR inhibitor that suppresses T-cell and B-cell proliferation. Tacrolimus is a calcineurin inhibitor that blocks T-cell activation by preventing IL-2 production. Prednisone is a corticosteroid that broadly suppresses immune cell function. Together, they provide synergistic immunosuppression to prevent allograft rejection.","oneSentence":"This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:04.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal transplant recipients"}]},"trialDetails":[{"nctId":"NCT07083830","phase":"PHASE1","title":"ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-30","conditions":"Kidney Transplant Failure and Rejection, Kidney Transplant; Complications","enrollment":24},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":"Kidney Transplant Infection","enrollment":1209},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT01239472","phase":"PHASE4","title":"Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant","status":"COMPLETED","sponsor":"Andre Barreto Pereira","startDate":"2011-01","conditions":"Renal Transplant Rejection, Immunosuppression","enrollment":30},{"nctId":"NCT02954198","phase":"NA","title":"Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-12-01","conditions":"Immunosuppression","enrollment":40},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT01895049","phase":"PHASE4","title":"Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria","status":"COMPLETED","sponsor":"Helio Tedesco Silva Junior","startDate":"2013-08","conditions":"Kidney Transplantation, Cytomegalovirus","enrollment":171},{"nctId":"NCT01276834","phase":"PHASE4","title":"Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation","status":"TERMINATED","sponsor":"Dianet Dialysis Centers","startDate":"2010-09","conditions":"Renal Transplantation","enrollment":13},{"nctId":"NCT00369161","phase":"PHASE4","title":"A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-06","conditions":"Renal Transplantation","enrollment":228},{"nctId":"NCT01624948","phase":"PHASE4","title":"Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-09","conditions":"BK Virus Infection","enrollment":40},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT01469884","phase":"PHASE4","title":"Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients","status":"COMPLETED","sponsor":"Irmandade Santa Casa de Misericórdia de Porto Alegre","startDate":"2011-11","conditions":"Renal Allograft, Hepatitis C","enrollment":30},{"nctId":"NCT01354301","phase":"PHASE4","title":"Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2011-05","conditions":"Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection","enrollment":300},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT01927588","phase":"PHASE4","title":"Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients","status":"UNKNOWN","sponsor":"Fundação Pró Rim","startDate":"2013-08","conditions":"Cytomegalovirus Infections","enrollment":50},{"nctId":"NCT01399242","phase":"PHASE4","title":"Efficacy of Certican® in Combination With Myfortic® in Renal","status":"UNKNOWN","sponsor":"Hospital Universitário São José","startDate":"2011-08","conditions":"Disorder Related to Renal Transplantation","enrollment":40},{"nctId":"NCT01183247","phase":"PHASE4","title":"An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2008-07","conditions":"Comparative Study, Immunosuppressive Agents","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Certican","Tacrolimus","Prednisone"],"phase":"marketed","status":"active","brandName":"Everolimus+Tacrolimus+Prednisone","genericName":"Everolimus+Tacrolimus+Prednisone","companyName":"Fundação Pró Rim","companyId":"funda-o-pr-rim","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen inhibits T-cell proliferation and activation to prevent organ rejection after transplantation. Used for Prevention of organ rejection in renal transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}